Low-dose combination of perindopril arginine with indapamide in correction of metabolic syndrome
- Authors: Kseneva S.I.1, Borodulina E.V.1, Semiglazova T.A.1, Kulakova N.V.1, Tarasova I.V.1, Udut V.V.1, Kseneva SI2, Borodulina EV2, Semiglazova TA2, Kulakova NV2, Tarasova IV2, Udut VV2
-
Affiliations:
- Research Institute of Pharmacology of AMS Siberian Section, Tomsk
- Issue: Vol 83, No 10 (2011)
- Pages: 40-45
- Section: Editorial
- Submitted: 10.04.2020
- Published: 15.10.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30926
- ID: 30926
Cite item
Full Text
Abstract
Material and methods. Thirty hypertensive patients with MS received low-dose combined drug noliprel A (Servier, France). In weak hypotensive effect noliprel A forte was used. An antihypertensive (by the data of 24-h blood pressure monitoring), sympatholytic (by the levels of ACTH and cortisol in blood plasma, by variability of the heart rate)and metabolic effects of the drug were assessed after 3 weeks, 3 and 6 months of treatment.Carbohydrate metabolism was studied by glucose and insulin blood levels before meal and after it. Lipid and purin metabolism were assessed by enzyme method, leptin levels - by enzyme immunoassay.
Results. 24-h blood pressure monitoring registered a stable regular blood pressure lowering, target blood pressure was achieved in 78.6% patients. Blood ACTH concentration significantly reduced showing a sympatholytic action of the drug.Parameters of lipid, carbohydrate and purin metabolism changed insignificantly. Positive changes were seen in anthropometric indices, leptin tended to decrease. Changes in these parameters, sympatholytic and hypotensive effects depended on plasmic levels of leptin.
Conclusion. A fixed low-dose combination of perindopril arginine with indapamide in a stable hypotensive effect and metabolic neutrality influences some key components of MS including hyperactivity of sympathic autonomic nervous system component and hyperleptinemia.
About the authors
Svetlana Igorevna Kseneva
Email: viksbest@mail.ru
Elena Valentinovna Borodulina
Tat'yana Aleksandrovna Semiglazova
Natal'ya Vadimovna Kulakova
Irina Vadimovna Tarasova
Vladimir Vasil'evich Udut
S I Kseneva
Research Institute of Pharmacology of AMS Siberian Section, TomskResearch Institute of Pharmacology of AMS Siberian Section, Tomsk
E V Borodulina
Research Institute of Pharmacology of AMS Siberian Section, TomskResearch Institute of Pharmacology of AMS Siberian Section, Tomsk
T A Semiglazova
Research Institute of Pharmacology of AMS Siberian Section, TomskResearch Institute of Pharmacology of AMS Siberian Section, Tomsk
N V Kulakova
Research Institute of Pharmacology of AMS Siberian Section, TomskResearch Institute of Pharmacology of AMS Siberian Section, Tomsk
I V Tarasova
Research Institute of Pharmacology of AMS Siberian Section, TomskResearch Institute of Pharmacology of AMS Siberian Section, Tomsk
V V Udut
Research Institute of Pharmacology of AMS Siberian Section, TomskResearch Institute of Pharmacology of AMS Siberian Section, Tomsk
References
- Константинов B. O., Сайфулина Я. Р. Метаболический синдром - болезнь или случайный набор риск-факторов? Артер. гипертензия 2007; 13(3): 195-196.
- Ford E. S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabet. Care 2005; 28: 2745-2749.
- Адашева T. B., Демичева О. Ю. Метаболический синдром - основы патогенетической терапии. Лечащий врач 2003; 10: 24-28.
- Конради А. О. Ожирение, симпатическая гиперактивность и артериальная гипертензия - есть ли связь? Артер. гипертензия 2006; 12(2): 2-9.
- Bell-Anderson К. S., Bryson J. М. Leptin as a potential treatment for obesity: progress to date. Treat. Endocrinol. 2004; 3: 11-18.
- Daskalopoulou S. S., Mikhailidis D. P., Elisaf M. Prevention and treatment of metabolic syndrome. Angiology 2004; 55(6): 589-612.
- Оганов Р. Г., Мамедов M. H., Колтунов И. Е. Метаболический синдром: путь от научной концепции до клинического диагноза. Врач 2007; 3: 3-7.
- Чазова И. Е., Мычка В. Б. Метаболический синдром. М.: Медиа Медика; 2004.
- Бригов А. Н. Современные подходы к лечению артериальной гипертонии: учет других факторов риска и ассоциированных заболеваний. Трудный пациент 2006; 8: 65-70.
- Котовская Ю. В. Метаболический синдром: прогностическое значение и современные подходы к комплексной терапии. Сердце 2005; 4 (5): 236-241.
- Meigs J. B., Wilson W. F., Nathan D. M. et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes 2003; 52: 2160-2167.
- Grundy S. M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 2006; 5: 295-309.
- Giverts M. M. Manipulation of the renin-angiotensin system. Circulation 2001; 104(5): 14-18.
- Митченко Е. И. Метаболический синдром: состояние проблемы и лечебные подходы. Практична ангiол. 2006; 1: 14-18.
- Кобалава Ж. Д. Место комбинированной антигипертензивной терапии в современном лечении артериальной гипертонии. Клин. фармакол. и тер. 2001; 10(3): 1-5.
- Моисеев С. В. Симпатическая нервная система и метаболический синдром. Клин. фармакол. и тер. 2004; 4: 70-74.
- Eikelis N., Esler М. The neurobiology of human obesity. Exp. Physiol. 2005; 90(5): 673-682.
- Миронова T. B., Миронов B. A. Клинический анализ волновой структуры синусового ритма сердца. Челябинск; 1998.